Mycotopia Therapies, Inc.
TPIA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.05 | -0.01 |
| FCF Yield | -113.85% | -44.83% | -25.25% | -0.79% |
| EV / EBITDA | -0.80 | -1.89 | -1.65 | -5.92 |
| Quality | ||||
| ROIC | 76.76% | 65.77% | 1,046.95% | -258.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.14 | 0.09 | 0.24 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -142.62% | 83.74% | -175.63% | 21.33% |
| Safety | ||||
| Net Debt / EBITDA | -0.66 | -1.46 | -0.16 | 0.10 |
| Interest Coverage | 7.66 | 0.00 | -2.14 | -17.60 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -544.71 | -82,042.96 | -177,414.92 |